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Adult T cell leukemia (ATL) is one of the rare human
cancers initiated by a transforming retrovirus, HTLV-
I. After many years of controversy, it is now accepted
that the viral transactivator protein Tax plays a criti-
cal role in initiating the leukemic process, because
Tax transgenics develop a disease with striking ATL
features. However, its role in the maintenance of the
lymphoproliferation remains still a matter of debate.
Long-term prognosis of ATL patients remains extre-
mely poor. In acute ATL, well conducted Japanese
trials demonstrated that although combinations of
chemotherapy improved response rate, they failed to
achieve a significant impact on survival. Patients with
chronic and smoldering ATL have a better prognosis
but long-term survival is poor when these patients are
managed with a watchful-waiting policy or with che-
motherapy. We recently realized a worldwide meta-
analysis showing that the combination of zidovudine
and interferon-alpha (IFN) is highly effective in the
leukemic subtypes of ATL and should be considered
as standard first line therapy in that setting. This
combination has changed the natural history of the
disease through achievement of significantly improved
long-term survival in patients with smoldering and
chronic ATL as well as patients with acute ATL and
wild type p53. ATL lymphoma patients may benefit
from initial induction therapy based on aggressive
chemotherapy regimen in addition to or followed by
antiretroviral therapy with AZT/IFN. In all patients,
in order to prevent the occurrence of resistance and
relapse, clinical trials assessing bone marrow trans-
plantation additional targeted therapies such as
arsenic/IFN combination or monoclonal antibodies,
are mandatory after achieving CR. In that sense, we
recently reported that the combination of arsenic tri-
oxide, IFN, known to trigger Tax proteolysis in addi-
tion to zidovudine, yielded unprecedented response
rates in chronic ATL patients, and may prevent
relapses in ATL lymphoma responding patients after
chemotherapy. To investigate the molecular mechan-
ism of therapeutic action in vivo, we used Tax trans-
genic mice that develop a disease with striking ATL
features. We demonstrate that the combination of
a r s e n i ct r i o x i d ea n dI F Nc u r e sT a x - d r i v e nm u r i n e
ATLs through selective targeting of leukemia initiat-
ing cell (LIC) activity. Importantly, this effect requires
proteasome function. Overall, our findings strongly
suggest that in this model ATL LICs are addicted to
the iral Tax oncoprotein and open the prospect of
new strategies to cure ATL.
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